Top-Rated StocksTop-Rated Pacira BioSciences (PCRX) Stock Price, News & Analysis $28.06 +0.12 (+0.43%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$27.62▼$28.3350-Day Range$26.32▼$31.4952-Week Range$25.93▼$48.60Volume229,619 shsAverage Volume431,939 shsMarket Capitalization$1.30 billionP/E Ratio311.78Dividend YieldN/APrice Target$52.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Pacira BioSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside86.6% Upside$52.36 Price TargetShort InterestHealthy6.87% of Shares Sold ShortDividend StrengthN/ASustainability-1.89Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth33.33%From $2.16 to $2.88 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.62 out of 5 starsMedical Sector104th out of 940 stocksPharmaceutical Preparations Industry33rd out of 434 stocks 4.4 Analyst's Opinion Consensus RatingPacira BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.36, Pacira BioSciences has a forecasted upside of 86.6% from its current price of $28.06.Amount of Analyst CoveragePacira BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.87% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 11.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePacira BioSciences has received a 52.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.Environmental SustainabilityThe Environmental Impact score for Pacira BioSciences is -1.89. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows5 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 33.33% in the coming year, from $2.16 to $2.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 311.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 109.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 311.78, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 104.74.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pacira BioSciences Stock (NASDAQ:PCRX)Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Read More PCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCRX Stock News HeadlinesNovember 13, 2023 | finance.yahoo.comPacira (PCRX) Gets FDA Nod for Exparel's Label ExpansionNovember 10, 2023 | markets.businessinsider.comPacira Announces FDA Approval Of Expanded EXPAREL Label To Include Two Addl Nerve Block IndicationsDecember 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 10, 2023 | finance.yahoo.comPacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block IndicationsNovember 7, 2023 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in NovemberNovember 4, 2023 | finance.yahoo.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call TranscriptNovember 4, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)November 3, 2023 | finance.yahoo.comAre Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?December 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 2, 2023 | finance.yahoo.comPacira (PCRX) Q3 Earnings and Revenues Miss, '23 View UpdatedNovember 2, 2023 | seekingalpha.comPacira BioSciences, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 2, 2023 | finance.yahoo.comPacira BioSciences Inc (PCRX) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comPacira BioSciences Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | seekingalpha.comPacira BioSciences: Preparing For A Pivotal Q3 EarningsOctober 30, 2023 | seekingalpha.comPacira BioSciences: Sell-Off On Pain Relief Specialist - But Recovery Not GuaranteedOctober 26, 2023 | finance.yahoo.comPacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023October 24, 2023 | msn.comBarclays Maintains Pacira BioSciences (PCRX) Overweight RecommendationOctober 12, 2023 | finance.yahoo.comAmerican Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.October 6, 2023 | finance.yahoo.comLoss-making Pacira BioSciences (NASDAQ:PCRX) sheds a further US$83m, taking total shareholder losses to 50% over 3 yearsOctober 4, 2023 | msn.comRBC Capital Reiterates Pacira BioSciences (PCRX) Outperform RecommendationOctober 2, 2023 | finance.yahoo.comAmerican Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient CareSeptember 27, 2023 | finance.yahoo.comUnveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 27, 2023 | finance.yahoo.comUnraveling the Future of Pacira BioSciences Inc (PCRX): A Deep Dive into Key MetricsSeptember 26, 2023 | marketwatch.comPacira BioSciences Chairman, CEO David Stack to RetireSeptember 26, 2023 | msn.comPacira BioSciences CEO David Stack to step downSeptember 26, 2023 | finance.yahoo.comPacira BioSciences Announces Leadership Succession PlanSeptember 6, 2023 | finance.yahoo.comPacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment ConferenceSee More Headlines Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees715Year FoundedN/APrice Target and Rating Average Stock Price Target$52.36 High Stock Price Target$60.00 Low Stock Price Target$42.00 Potential Upside/Downside+86.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.09 Trailing P/E Ratio311.78 Forward P/E Ratio12.99 P/E GrowthN/ANet Income$15.91 million Net Margins1.05% Pretax Margin1.49% Return on Equity12.16% Return on Assets6.16% Debt Debt-to-Equity Ratio0.62 Current Ratio4.78 Quick Ratio3.74 Sales & Book Value Annual Sales$666.82 million Price / Sales1.95 Cash Flow$4.04 per share Price / Cash Flow6.95 Book Value$16.89 per share Price / Book1.66Miscellaneous Outstanding Shares46,440,000Free Float43,373,000Market Cap$1.30 billion OptionableOptionable Beta0.72 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. David M. Stack (Age 73)Chairman & CEO Comp: $1.54MMr. Charles A. Reinhart III (Age 62)CPA, M.B.A., Chief Financial Officer Comp: $780.58kMr. Daryl Gaugler (Age 61)Chief Operating Officer Comp: $778.77kMs. Kristen Williams J.D. (Age 49)Chief Administrative Officer & Secretary Comp: $799.63kMr. Anthony Molloy III (Age 49)Esq., Chief Legal & Compliance Officer Comp: $581.41kMs. Lauren Bullaro Riker (Age 44)Principal Accounting Officer & VP of Finance Comp: $288.81kSusan MescoHead of Investor RelationsMr. Richard KahrVice President of Human ResourcesDr. Roy Winston M.D. (Age 62)Chief Medical Officer & Orthopedic Franchise Comp: $996.94kMr. Dennis McLoughlin (Age 57)Chief Customer Officer Comp: $535.87kMore ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNALX OncologyNASDAQ:ALXOAtea PharmaceuticalsNASDAQ:AVIRSeres TherapeuticsNASDAQ:MCRBNektar TherapeuticsNASDAQ:NKTRView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 123,440 shares on 12/1/2023Ownership: 0.676%Deutsche Bank AGSold 51,895 shares on 11/24/2023Ownership: 0.393%Public Sector Pension Investment BoardSold 24,261 shares on 11/22/2023Ownership: 0.124%Graham Capital Management L.P.Bought 8,041 shares on 11/22/2023Ownership: 0.017%Walleye Trading LLCBought 100 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PCRX Stock Analysis - Frequently Asked Questions Should I buy or sell Pacira BioSciences stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PCRX shares. View PCRX analyst ratings or view top-rated stocks. What is Pacira BioSciences' stock price target for 2024? 9 Wall Street research analysts have issued 1-year price objectives for Pacira BioSciences' shares. Their PCRX share price targets range from $42.00 to $60.00. On average, they predict the company's share price to reach $52.36 in the next year. This suggests a possible upside of 86.6% from the stock's current price. View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts. How have PCRX shares performed in 2023? Pacira BioSciences' stock was trading at $38.61 on January 1st, 2023. Since then, PCRX stock has decreased by 27.3% and is now trading at $28.06. View the best growth stocks for 2023 here. When is Pacira BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our PCRX earnings forecast. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings results on Thursday, November, 2nd. The company reported $0.52 EPS for the quarter, missing the consensus estimate of $0.65 by $0.13. The company earned $163.93 million during the quarter, compared to the consensus estimate of $172.83 million. Pacira BioSciences had a net margin of 1.05% and a trailing twelve-month return on equity of 12.16%. What ETFs hold Pacira BioSciences' stock? ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What is Dave Stack's approval rating as Pacira BioSciences' CEO? 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA). Who are Pacira BioSciences' major shareholders? Pacira BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (3.53%), Clearbridge Investments LLC (2.48%), Rock Springs Capital Management LP (2.27%), Rice Hall James & Associates LLC (2.09%), Schroder Investment Management Group (1.44%) and Jennison Associates LLC (1.34%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PCRX) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.